BLFS

Based on BioLife Solutions, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does BioLife Solutions do?

BioLife Solutions develops and manufactures tools used in cell and gene therapy research and commercial manufacturing. Its core products include biopreservation media, automated thawing systems, cold-chain shipping containers, and cryogenic storage equipment. The company serves customers across North America, Europe, the Middle East, Africa, and other international markets.

Does BLFS pay dividends?

No, BioLife Solutions does not currently pay a dividend. The company is focused on reinvesting resources into product development and market expansion within the growing cell and gene therapy supply chain. Investors seeking regular income should account for the absence of a dividend.

When does BLFS report earnings?

BioLife Solutions follows a standard quarterly earnings cadence for US-listed companies. For the exact schedule and most recent results, check the investor relations section of the company's official website.

Is BLFS a good stock to buy?

UQS Score rates BLFS as Below Average overall. The Growth pillar is a positive, but Weak Quality and Moat ratings alongside an Elevated Valuation suggest meaningful risks. Investors should weigh the growth opportunity against the lack of a durable competitive advantage and current pricing. The full pillar breakdown is available to UQS Pro members.

Is BLFS overvalued?

The UQS Valuation pillar for BLFS is rated Elevated, which indicates the stock may be priced above what the underlying business fundamentals would typically support. This does not guarantee a price decline, but it does suggest limited margin of safety if the company's growth trajectory disappoints.

How does BLFS compare to its competitors?

Compared to peers like Azenta, BLFS operates in a narrower niche focused on biopreservation and cold-chain tools for cell and gene therapy. Its smaller scale and Weak Moat rating suggest it has less pricing power and fewer diversified revenue streams than larger life-science tool companies.

What is BLFS's market cap bracket?

BioLife Solutions is classified as a small-cap company. This places it in a category where liquidity can be lower and share price volatility tends to be higher than large- or mega-cap peers. Small-cap stocks can offer growth potential but typically carry elevated risk.

Who founded BioLife Solutions?

BioLife Solutions was incorporated in 1987 and has evolved over decades into a focused supplier for the cell and gene therapy industry. For detailed founding history and leadership background, the company's official about page and SEC filings are the most reliable sources.

Is BLFS a long-term quality indicator?

From a long-term quality standpoint, BLFS presents a mixed picture. The Good Growth pillar reflects a real and expanding market opportunity in cell and gene therapy. However, the Weak Quality and Moat pillars indicate the company has not yet demonstrated the durable competitive advantages typically associated with high-quality long-term holdings.

What is the main competitive advantage of BioLife Solutions?

BioLife Solutions' primary edge lies in its specialized biopreservation media formulations — particularly HypoThermosol FRS and CryoStor — which are designed to reduce cell damage during freezing and thawing. However, the UQS Moat pillar rates this advantage as Weak, suggesting competitors could replicate or substitute these offerings over time.

What sector does BLFS belong to?

BLFS operates in the Healthcare sector, specifically within the life-science tools and services segment. It focuses on the upstream supply chain for cell and gene therapy, providing the preservation media, equipment, and logistics tools that therapy developers depend on during research and manufacturing.

BioLife Solutions, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

BioLife Solutions, Inc. is growing rapidly with strong revenue and earnings expansion.

BioLife Solutions, Inc. maintains a reasonable risk profile with manageable debt levels.

BioLife Solutions, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.

BioLife Solutions, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BLFS.

The UQS (Unified Quality Score) for BioLife Solutions, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses BioLife Solutions, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether BioLife Solutions, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.